Landmark Longevity Summits at King's College London Demonstrate That Top Financial and Tech Corporations Are Committed to Longevity
The Landmark International Longevity Policy, Governance and AI for Longevity Summits, Featuring Presentations and Panels from Top Executives of Prudential, AXA, HSBC, L&G, Microsoft and NVIDIA, Reveal the Future Intersection of AI, Policy, Finance and Longevity
This week two Landmark International Longevity Summits in London attracted the attention of scientists, government officials, major financial corporations, insurance companies, investment banks, and technology companies from around the world. The Landmark AI for Longevity Summit and the First International Longevity Policy and Governance Summit at King's College London are expected to become the world-leading forums for the Longevity Industry.
Longevity for AI Summit
The AI for Longevity Summit featured talks from top executives from Prudential, HSBC, AXA Insurance, NVIDIA, Microsoft, Babylon Health, Insilico Medicine, Longevity.Capital, Longevity Vision Fund, Juvenescence, Deep Knowledge Ventures, and the UK All-Party Parliamentary Group for Longevity. The International Longevity Policy and Governance Summit focused on the efforts of longevity-progressive governments to transform the challenge of rapidly ageing populations into the opportunity of healthy longevity, drawing on experience from Japan, Israel, Switzerland, US, and UK.
The Deep Knowledge Group has developed sophisticated methods for translating advanced AI for Longevity solutions. Together with its subsidiaries, the company has developed advanced frameworks and technologies including novel applications of life data for insurance companies, pension funds, healthcare companies, and government bodies. These new technologies and instruments at the forefront of the rising Longevity Financial Industry provide practical applications of preventive medicine and Precision Health.
Dmitry Kaminskiy, founder of Deep Knowledge Group presented two special analytical case-studies at the Summit. The first entitled “Global Longevity Governance: 50 Countries Big Data Comparative Analysis of Longevity Progressiveness” featured benchmarking of 50 nations. Researchers from Aging Analytics Agency used 200 parameters per country and 10,000 data points in total to rank 50 countries according to their respective levels of Healthy Longevity. The study revealed gaps between health-adjusted life expectancy and unadjusted life expectancy and provided tangible policy recommendations on how to these nations could optimize their National Healthy Longevity.
“We need nations to begin to marshal their resources to leverage the opportunities of healthy longevity. What is critical now is to maximize the opportunity of healthy longevity in as socially-inclusive a manner as possible and share the longevity dividend equitably around the world”
- Dmitry Kaminskiy, Director of International Cooperation, Longevity International UK.
Dmitry Kaminskiy also delivered a presentation with highlights from Aging Analytics Agency’s new report entitled “Biomarkers of Longevity: Most Comprehensive and Minimum Required Panels of Biomarkers of Aging”.
This report utilizes comprehensive analytical frameworks to benchmark biomarkers of aging, health and Longevity using ratios of accuracy vs actionability in order to present a “Minimum Viable Panel” of Longevity biomarkers that are precise enough and immediately implementable in practice. This highlights the increasingly necessary role that AI will play in coordinating the practical implementation of Longevity biomarkers due to the sheer volume of life and health data involved.
“AI for Longevity is an underrepresented sector in the Longevity Industry despite having more potential to increase healthy Longevity in the short term than any other sector. It is our aim to change that with the launch of the Longevity AI Consortium at King’s College London, which will work to facilitate the shift from treatment to prevention and from preventive medicine to real-world precision health.” - Dmitry Kaminskiy, Managing Partner of Deep Knowledge Group.
Speakers and delegates at the Summit shared learnings from the UK, Japan, Israel and other countries successfully mobilising the opportunities longer lives can bring. International policymakers and major corporate players in finance, insurance, investment, science, pharma and tech exchanged their experiences and ideas on beginning to working together in a new ‘social contract’ to enhance global prosperity equitably.
“Unless drastic action is taken, people will suffer lower quality wellbeing during a longer lifespan. This could become the next global crisis after climate change. The Longevity AI Consortium is unique in its focus on preventive health, addressing the social determinants of health at the root of inequalities.”
- Tina Woods, CEO, Longevity International UK.
The Longevity AI Consortium
The Longevity AI Consortium at King’s College London, which launched this week will work to facilitate the shift from treatment to prevention and from preventive medicine to real-world Precision Heath. Deep Knowledge Ventures has long recognized the importance of this sector, and one of our very first investments was in an AI for Longevity startup in 2014. It remains a large focus of our strategic agenda to this day, and will be one of the most heavily prioritized sectors of the target investment portfolio of our new Longevity-focused hybrid investment fund Longevity.Capital.
“AI holds enormous potential to rapidly accelerate the implementation of Longevity R&D. The nation is home to multiple centres of AI for Healthcare, but not a single Longevity AI Consortium. We are changing this through our unique academic-industry focus on preventive and personalised physical, mental and financial health, marking us out from other AI and Ageing centres around the world”
- Richard Siow, Ph.D., Director, Longevity AI Consortium, King’s College London.
The initial focus will be on core longevity academic-industry R&D, including the development of biomarkers of aging and novel implementation of life and health data analytics. In 2020, after achieving several key scientific and funding milestones, AI-enabled solutions for physical, mental and financial wellness will become a major focus, and an AI Longevity Accelerator will be launched to serve as a much-needed bridge between start-ups and major UK investors, creating for the first time a dedicated infrastructure for increased investments and developments in this important sector.
The Longevity AI Consortium will serve as a leading academic-industry R&D hub for AI-driven personalised and preventive diagnostics, prognostics and therapeutics. The advances in genetics, artificial intelligence and the growing availability of health data present an opportunity to develop advanced personalised consumer and patient care. The aim of the Longevity AI Consortium include the identification of novel longevity and healthy ageing biomarkers, accelerated diagnosis of age-related health decline, with increased accuracy, refining demographic and clinical methods to facilitate recruitment, retention and ongoing reappraisal, the development of personalised physical, mental and financial health and longevity to better implement and promote effective healthy lifestyles for longevity, such as modifying patterns in sleep, nutrition, physical activity, environmental exposure and financial planning.
“The application of AI for Longevity will bring the greatest real-world benefits to the industrialization of Longevity to scale, and will serve as the main driver of progress in the widespread extension of Healthy Longevity for all segments of society.”
- Dmitry Kaminskiy, Senior Advisor to the AI Longevity Consortium at King’s College London.
Deep Knowledge Group Managing Partner Dmitry Kaminskiy also chaired a panel discussion on “Investing in AI for Longevity” among top executives of HSBC, Longevity Vision Fund and Juvenescence, distilling just a few of the advanced methodologies and frameworks that Deep Knowledge Group uses to make relevant, intelligent investments in this sector.
Eric Kihlstrom, Managing Partner at Longevity.Capital and Strategic Director of Aging Analytics Agency delivered a presentation on the Global Longevity Landscape with highlights from UK, EU, US.
"The United Kingdom is in a unique position, having prioritised both its longevity and AI industries in two of its four Industrial Strategy Grand Challenges. Given its strengths in AI and longevity, and its expertise as a global leader in fintech and life sciences, it can develop the healthy longevity marketplace to scale internationally.”
- Eric Kihlstrom, Director of Industry Collaboration, Longevity International UK.
The International Longevity and Policy Summit was held alongside the AI for Longevity Summit, organized by the Longevity AI Consortium. Both events were organised with the strategic support of Deep Knowledge Group, Aging Research at King’s, the Biogerontology Research Foundation, Aging Analytics Agency and Collider Health.
The UK is a global leader in life sciences, financial services, and technology and the UK Government has made substantial economic and policy commitments in the area of healthy ageing. A positive narrative and a bold vision are needed to excite the business community, convince policymakers and convert hearts and minds in the wider public to leverage the opportunities of healthy, longer lives and maximise the health and wealth of the nation.
Major Topics Discussed at the Summits
1. Frontier applications of AI in aging research, Longevity R&D and the development of biomarkers of health and Longevity
2. The paradigm shift from disease treatment and sick care to preventive medicine, and from preventive medicine to precision health, utilizing nearly real-time assessment of biomarkers of aging to coordinate micro-dose interventions to continually rebalance biomarkers of health and Longevity and maintain an optimal state of precision health, and how AI will be necessary for the coordination of biomarker monitoring and interventions due to the sheer volume of data
3. The disruptive and accelerative impact that AI is having on Longevity R&D and the practical implementation and clinical translation of Longevity technologies and therapeutics.
4. The increasing shift toward actionable biomarkers of aging, including the identification of biomarkers of health, Longevity and aging that have the highest ratios of accuracy and precision vs. actionability, expense and ease-of-implementation, and the benchmarking of biomarkers that can be used in practice today
5. Novel methods of using AI to optimize psychological wellness, social activity, promote neuroplasticity and combat loneliness and social isolation among elderly.
6. Emerging trends and novel paradigms relating to both the creation and application of life data collected on a massive scale from healthy individuals and used in scientifically-backed, quantifiable, tangible and precise ways to preserve and maintain an optimal state of health.
7. The convergence of AI and advanced biomedicine presents an opportunity to shift from traditional healthcare to AI-empowered precision health and to make personalized preventive care and the maintenance of Healthy Human Longevity a reality.
8. Frontier applications of AI for financial wellness over extended periods of healthy Longevity, and the maintenance and optimization of “wealthspan” to complement advances in “healthspan”, including the application of AI assistants and “robo-advisors” for personal financial management, and the utilization of novel forms of financial data to enable AI-empowered AgeTech and WealthTech services.
Introducing Longevity Industry 1.0
Speakers, panelists and attendees were also treated to free copies of an early summary of the upcoming book, “Longevity Industry 1.0: Defining the Most Complex Industry in Human History” by Deep Knowledge Group partners Dmitry Kaminskiy and Margaretta Colangelo.
In the book, seasoned Longevity industry professionals Dmitry Kaminskiy and Margaretta Colangelo distill the complex assembly of deep market intelligence and industry knowledge that they have developed over the past 5 years into a full-scope understanding of the global Longevity Industry, showing the public exactly how they managed to define the overwhelmingly complex and multidimensional Longevity Industry for the first time, and how they created tangible framework for its systematization and forecasting.
The book is available now available for ore-order here: https://www.longevity-book.com
About Deep Knowledge Group
Deep Knowledge Group is a consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, FinTech, GovTech, InvestTech), ranging from scientific research to investment, entrepreneurship, media, analytics and more. Its subsidiaries and associated organisations include Deep Knowledge Ventures, Longevity.Capital, AI-Pharma.Capital, Longevity FinTech Company, Deep Knowledge Analytics, Aging Analytics Agency, Biogerontology Research Foundation, Longevity Swiss Foundation, Longevity International UK - Secretariat for the UK All-Party Parliamentary on Longevity, and AI-Longevity Consortium at King’s College London.
About Aging Analytics Agency
Aging Analytics Agency is the world’s premier provider of industry analytics on the topics of Longevity, Precision Preventive Medicine and Economics of aging, and the convergence of technologies such as AI and Digital Health and their impact on healthcare. The company provides strategic consulting services in fields related to Longevity, and currently serves as the primary source of analytics for the specialized hybrid hedge fund Longevity.Capital, as well as the UK All-Party Parliamentary Group for Longevity.
About the Longevity AI Consortium
The Longevity AI Consortium serves as a leading R&D hub and industry-academic hotspot for advanced AI-driven personalised preventive diagnostics, prognostics and therapeutics. The advances in genetics, artificial intelligence and the growing availability of health data present an opportunity to make precise personalised patient care a clinical reality. The aims of the Longevity AI Consortium include the identification of novel longevity and healthy ageing biomarkers, accelerated diagnosis of age-related health decline, with increased accuracy, refining demographic and clinical methods to facilitate recruitment, retention and ongoing reappraisal, the development of personalised health, longevity and treatment practices, and promoting effective healthy lifestyles for longevity, such as modifying patterns in sleep, nutrition, physical activity and environmental exposure.
About Longevity International UK
Longevity International is a social enterprise bringing together startups, industry, academic and governmental stakeholders to provide a unified voice and coordinating vehicle for positive discourse and change to ensure the ‘longevity dividend’ is accessible to everyone. The UK is a global leader in life sciences, financial services, and technology and the UK Government has made substantial economic and policy commitments in the area of healthy ageing. A positive narrative and a bold vision are needed to excite the business community, convince policymakers and convert hearts and minds in the wider public to leverage the opportunities of healthy, longer lives and maximise the health and wealth of the nation.